Abstract |
Chemotherapy-induced cognitive impairment (CICI) occurs in a substantial proportion of treated cancer patients, with no drug currently available for its therapy. This study investigated whether PAN-811, a ribonucleotide reductase inhibitor, can reduce cognitive impairment and related suppression of neurogenesis following chemotherapy in an animal model. Young adult rats in Chemo and Chemo+PAN-811 groups received 3 intraperitoneal (i.p.) injections of methotrexate (MTX) and 5-fluorouracil (5-FU), and those in Saline and Saline+PAN-811 groups received equal volumes of physiological saline at 10-day intervals. PAN-811 in saline was delivered through i.p. injection, 10 min following each saline (Saline+PAN-811 group) or MTX/5-FU (Chemo+PAN-811 group) treatment, while equal volumes of saline were delivered to Saline and Chemo groups. Over Days 31-66, rats were administered tests of spatial memory, nonmatching-to-sample rule learning, and discrimination learning, which are sensitive to dysfunction in hippocampus, frontal lobe and striatum, respectively. On Day 97, neurogenesis was immnunohistochemically evaluated by counting doublecortin-positive (DCX+) cells in the dentate gyrus (DG). The results demonstrated that the Chemo group was impaired on the three cognitive tasks, but co-administration of PAN-811 significantly reduced all MTX/5-FU-induced cognitive impairments. In addition, MTX/5-FU reduced DCX+ cells to 67% of that in Saline control rats, an effect that was completely blocked by PAN-811 co-administration. Overall, we present the first evidence that PAN-811 protects cognitive functions and preserves neurogenesis from deleterious effects of MTX/5-FU. The current findings provide a basis for rapid clinical translation to determine the effect of PAN-811 on CICI in human.
|
Authors | Zhi-Gang Jiang, Gordon Winocur, J Martin Wojtowicz, Olga Shevtsova, Steven Fuller, Hossein A Ghanbari |
Journal | PloS one
(PLoS One)
Vol. 13
Issue 1
Pg. e0191866
( 2018)
ISSN: 1932-6203 [Electronic] United States |
PMID | 29370277
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Dcx protein, rat
- Doublecortin Protein
- Enzyme Inhibitors
- Neuroprotective Agents
- Pyridines
- Thiosemicarbazones
- 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
- Ribonucleotide Reductases
- Fluorouracil
- Methotrexate
|
Topics |
- Animals
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Cognitive Dysfunction
(chemically induced, prevention & control)
- Dentate Gyrus
(drug effects)
- Discrimination Learning
(drug effects)
- Disease Models, Animal
- Doublecortin Protein
- Enzyme Inhibitors
(pharmacology)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Hippocampus
(drug effects, pathology, physiopathology)
- Humans
- Learning
(drug effects)
- Methotrexate
(administration & dosage, adverse effects)
- Neurogenesis
(drug effects)
- Neuroprotective Agents
(pharmacology)
- Pyridines
(pharmacology)
- Rats
- Rats, Long-Evans
- Ribonucleotide Reductases
(antagonists & inhibitors)
- Spatial Memory
(drug effects)
- Thiosemicarbazones
(pharmacology)
|